The Early Detection Research Network has helped six cancer diagnostic tests achieve FDA-approval.

1. One combined test to assess the risk for hepatocellular cancer: DCP and AFP-L3
2. Two tests help to determine the need for prostate biopsies: %[2]proPSA and PCA3
3. Three tests help to predict risk of ovarian cancer in women with a pelvic mass: OVA1^TM, Overa^TM and a combined test known as ROMA^TM with CA125 and HE4